Journal Mobile Options
Table of Contents
Vol. 82, No. 6, 2012
Issue release date: July 2012
Oncology 2012;82:327–332

Chemotherapy-Related Thrombocytosis: Does It Increase the Risk of Thromboembolism?

Ahmed S. · Shahid R.K. · Bhatt H. · Lee-Ying R. · Lim J.
aDepartment of Oncology, Saskatoon Cancer Center, and Departments of bCommunity Health and Epidemiology and cMedicine, University of Saskatchewan, Saskatoon, Sask., Canada

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objectives: Chemotherapy increases the risk of thromboembolism in patients with cancer. Although thrombocytopenia is a known side effect of chemotherapy, reactive thrombocytosis related to chemotherapy is uncommonly reported. The present study aimed to determine the incidence of gemcitabine-related thrombocytosis and the associated risk of thromboembolism. Methods: Medical records of 250 consecutive patients with a malignant disease who received gemcitabine-based therapy were reviewed. A multivariate analysis was done to determine factors associated with thromboembolism. Results: A total of 220 eligible patients with a median age of 63 years (range 26–83) were identified. Of these 220 patients, 95% had advanced malignancy and 59% had received prior chemotherapy. A total of 69% of patients received a platinum combination. In all, 46% patients experienced thrombocytosis following chemotherapy, with a median platelet count of 632 × 109/l (range 457–1,385). Twenty-three of the 220 patients experienced a vascular event within 6 weeks of treatment. Eleven patients with thrombocytosis experienced a vascular event compared with 10 patients without thrombocytosis (not significant). On multivariate analysis, leukocytosis (odds ratio 5.8, 95% confidence interval 2.1–15.8) and comorbid illnesses (odds ratio 4.1, 95% confidence interval 1.4–12.6) were correlated with thromboembolism. Conclusions: Although gemcitabine-based therapy has been associated with an increased incidence of thrombocytosis, it does not increase the risk of thromboembolism in cancer patients. Leukocytosis and comorbid illnesses do increase the risk of thromboembolism.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Blom JW, Doggen CJ, Osanto S, Rosendaal FR: Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715–722.
  2. Prandoni P, Falanga A, Piccioli A: Cancer and venous thromboembolism. Lancet Oncol 2005;6:401–410.
  3. Khorana AA, Connolly GC: Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009;27:4839–4847.
  4. Haddad TC, Greeno EW: Chemotherapy-induced thrombosis. Thromb Res 2006;118:555–568.
  5. Lechner D, Weltermann A: Chemotherapy-induced thrombosis: a role for microparticles and tissue factor? Semin Thromb Hemost 2008;34:199–203.
  6. Zecchina G, Ghio P, Bosio S, et al: Reactive thrombocytosis might contribute to chemotherapy-related thrombophilia in patients with lung cancer. Clin Lung Cancer 2007;8:264–267.
  7. Khorana AA, Francis CW, Culakova E, et al: Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005;104:2822–2829.
  8. Liumbruno G, Centoni PE, Ceretelli S, et al: Rapid reduction of platelet numbers in thrombocytosis. Ther Apher 2000;4:374–376.
  9. Esteban E, Fra J, Corral N, et al: Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer. Invest New Drugs 2002;20:73–82.
  10. Zwitter M, Kovac V, Smrdel U, et al: Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Anticancer Drugs 2005;16:1129–1134.
  11. Plunkett W, Huang P, Searcy CE, et al: Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996;23:3–15.
  12. Esteban E, Fra J, Sala M, et al: Phase I/II study of gemcitabine and vinorelbine plus cisplatin in non-small cell lung cancer. Invest New Drugs 2002;20:317–326.
  13. Radley JM, Hodgson GS, Thean LE, et al: Increased megakaryocytes in the spleen during rebound thrombocytosis following 5-flurouracil. Exp Hematol 1980;8:1129–1138.
  14. Hunt P, Zsebo KM, Hokom MM, et al: Evidence that stem cell factor is involved in the rebound thrombocytosis that follows 5-flurouracil treatment. Blood 1992;80:904–911.
  15. Connolly GC, Khorana AA, Kuderer NM, et al: Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res 2010;126:113–118.
  16. Khorana AA, Kuderer NM, Culakova E, et al: Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902–4907.
  17. Belch JF: The white blood cell as a risk factor for thrombotic vascular disease. Vasc Med 1990;1:203–213.

    External Resources

  18. Madjid M, Awan I, Willerson JT, Casscells SW: Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 2004;44:1945–1956.
  19. Connolly GC, Khorana AA: Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res 2010;125(suppl 2):S1–S7.

    External Resources

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50